Literature DB >> 12627361

Progressive vaccinia.

Mike Bray1, Mary E Wright.   

Abstract

The resumption of smallpox vaccination for health care workers and other first responders has raised concern about the occurrence of complications in people with immunodeficiency disorders, including those infected with human immunodeficiency virus. During the era of universal vaccination, roughly 1 person per million vaccinees in the general population developed progressive vaccinia, which is characterized by the relentless outward spread of infection from the vaccination site and eventual dissemination to other areas on the body. Review of 56 cases reported in the English-language medical literature from 1893 through 1997 indicates that the condition occurred only in persons with severe cell-mediated immunodeficiency. Progressive vaccinia was found to be lethal in infants who completely lacked cellular immune function, but infection resolved in many adults with acquired immunodeficiency. Almost all cases were treated with vaccinia immune globulin, but its efficacy has never been tested in a placebo-controlled trial. Further research is needed to develop effective forms of therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12627361     DOI: 10.1086/374244

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  34 in total

1.  Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function.

Authors:  Vijay Panchanathan; Geeta Chaudhri; Gunasegaran Karupiah
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  5-(Dimethoxymethyl)-2'-deoxyuridine: a novel gem diether nucleoside with anti-orthopoxvirus activity.

Authors:  Xuesen Fan; Xinying Zhang; Longhu Zhou; Kathy A Keith; Earl R Kern; Paul F Torrence
Journal:  J Med Chem       Date:  2006-06-01       Impact factor: 7.446

3.  Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques.

Authors:  Graham J Hatch; Victoria A Graham; Kevin R Bewley; Julia A Tree; Mike Dennis; Irene Taylor; Simon G P Funnell; Simon R Bate; Kimberley Steeds; Thomas Tipton; Thomas Bean; Laura Hudson; Deborah J Atkinson; Gemma McLuckie; Melanie Charlwood; Allen D G Roberts; Julia Vipond
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

4.  Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.

Authors:  Donald F Smee
Journal:  Future Virol       Date:  2013-09       Impact factor: 1.831

5.  Obligatory requirement for antibody in recovery from a primary poxvirus infection.

Authors:  Geeta Chaudhri; Vijay Panchanathan; Horst Bluethmann; Gunasegaran Karupiah
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 6.  Orthopoxvirus targets for the development of antiviral therapies.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Curr Drug Targets Infect Disord       Date:  2005-03

Review 7.  Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.

Authors:  Stephen R Walsh; Raphael Dolin
Journal:  Expert Rev Vaccines       Date:  2011-08       Impact factor: 5.217

8.  Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection.

Authors:  Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  PLoS Pathog       Date:  2010-03-12       Impact factor: 6.823

9.  The mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy.

Authors:  Xueying Ma; Ren-Huan Xu; Felicia Roscoe; J Charles Whitbeck; Roselyn J Eisenberg; Gary H Cohen; Luis J Sigal
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

10.  Diverse recognition of conserved orthopoxvirus CD8+ T cell epitopes in vaccinated rhesus macaques.

Authors:  Stephen R Walsh; Jacqueline Gillis; Björn Peters; Bianca R Mothé; John Sidney; Alessandro Sette; R Paul Johnson
Journal:  Vaccine       Date:  2009-06-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.